Disc Medicine Files 8-K with Updates
Ticker: IRON · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1816736
| Field | Detail |
|---|---|
| Company | Disc Medicine, Inc. (IRON) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-update
TL;DR
Disc Medicine filed an 8-K on Jan 10, 2025, with updates and exhibit info. Formerly Gemini Therapeutics.
AI Summary
Disc Medicine, Inc. filed an 8-K on January 10, 2025, reporting on various events. The filing includes information about financial statements and exhibits, and other events. The company was formerly known as Gemini Therapeutics, Inc. and FS Development Corp. before changing its name on February 9, 2021, and July 2, 2020, respectively.
Why It Matters
This 8-K filing provides important updates and disclosures for Disc Medicine, Inc., which may affect investor understanding of the company's current status and historical changes.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting on general corporate events and exhibits, not indicating any immediate material adverse changes.
Key Players & Entities
- Disc Medicine, Inc. (company) — Registrant
- Gemini Therapeutics, Inc. (company) — Former company name
- FS Development Corp. (company) — Former company name
- January 10, 2025 (date) — Date of report
- 001-39438 (other) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Disc Medicine, Inc.?
The 8-K filing serves as a current report for Disc Medicine, Inc., detailing Regulation FD disclosures, other events, and financial statements and exhibits as of January 10, 2025.
When did Disc Medicine, Inc. change its name from Gemini Therapeutics, Inc.?
Disc Medicine, Inc. changed its name from Gemini Therapeutics, Inc. on February 9, 2021.
What is the principal executive office address for Disc Medicine, Inc.?
The principal executive offices of Disc Medicine, Inc. are located at 321 Arsenal Street, Suite 101, Watertown, Massachusetts 02472.
What is the Commission File Number for Disc Medicine, Inc.?
The Commission File Number for Disc Medicine, Inc. is 001-39438.
What is the IRS Employer Identification Number for Disc Medicine, Inc.?
The IRS Employer Identification Number for Disc Medicine, Inc. is 85-1612845.
Filing Stats: 683 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-10 09:04:43
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share IRON The Nasdaq Global Ma
Filing Documents
- iron-20250110.htm (8-K) — 44KB
- iron-ex99_1.htm (EX-99.1) — 36KB
- img57926557_0.jpg (GRAPHIC) — 19KB
- img57926557_1.jpg (GRAPHIC) — 19KB
- 0000950170-25-003859.txt ( ) — 251KB
- iron-20250110.xsd (EX-101.SCH) — 24KB
- iron-20250110_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 10, 2025, Disc Medicine, Inc. (the "Company") issued a press release outlining the Company's recent pipeline and operational progress and strategic priorities for 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.
01 Other Events
Item 8.01 Other Events. The Company expects to report a material weakness in its internal control over financial reporting in the Company's annual report on Form 10-K for the year ended December 31, 2024. This material weakness is related to a lack of design and maintenance of effective Information Technology General Controls ("ITGC") over certain key financial IT systems. As a result, the related business process controls (IT application controls and IT-dependent manual controls) that are dependent on the ineffective ITGCs, or that use information produced from the systems impacted by the ineffective ITGCs, were also ineffective. To date, the Company has not identified any misstatements in its financial statements. The Company's independent registered public accounting firm has not completed its audit of the Company's internal control over financial reporting and, accordingly, does not express an opinion on or any other assessment of it.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Disc Medicine, Inc. on January 10, 2025, furnished herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: January 10, 2025 By: /s/ John Quisel, J.D., Ph.D. Name: John Quisel, J.D., Ph.D. Title: Chief Executive Officer